OS Therapies Inc. reported its financial results for the second quarter of 2025, noting a net operating loss of $4.537 million, compared to a net operating loss of $1.557 million in the same quarter of 2024. This increase in net loss is primarily attributed to expenses associated with regulatory activities related to the OST-HER2 Phase 2b osteosarcoma program. The net loss per share was $0.19 for Q2 2025 on 25.114 million weighted average shares outstanding, compared to a net loss of $0.26 per share on 5.991 million weighted average shares outstanding in Q2 2024. Significant corporate developments included the confirmation by the U.S. FDA that OST-HER2 meets the biological definition of Regenerative Medicine Advanced Therapy (RMAT), and the issuance of a BLA number in preparation for an Accelerated Approval submission. OS Therapies has also made progress internationally, with the initiation of the regulatory process for OST-HER2 with the UK's MHRA, and a scheduled rapporteur meeting with the European Medicines Agency $(EMA)$ to begin the approval process in Europe. The company successfully raised $4.2 million through a warrant exercise inducement and exchange offering, providing a cash runway into mid-2026, and entered into an At-The-Market $(ATM.UK)$ offering sales agreement to potentially raise up to $18 million through the sale of its common stock.